Research programme: autoimmune disorder therapeutics - Regen BioPharmaAlternative Names: NR2F6 activators - Regen BioPharma; Nuclear Receptor Subfamily 2, Group F, Member 6 activators - Regen BioPharma; RG-NA 01; RG-NI 01; RG-NI 02
Latest Information Update: 22 Sep 2016
At a glance
- Originator Regen BioPharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cytoplasmic and nuclear receptor agonists; Immunosuppressants; Interferon gamma modulators; Interleukin 17 modulators; Interleukin 2 modulators; Tumour necrosis factor alpha modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders